Avoid Co-Prescribing Diazepam and Oxycodone
Clinicians should avoid prescribing opioids and benzodiazepines concurrently whenever possible due to the profound risk of respiratory depression, coma, and death. 1
Primary Risks
The combination of diazepam (benzodiazepine) and oxycodone (opioid) creates life-threatening dangers through multiple mechanisms:
- Profound sedation and respiratory depression that can progress to coma and death 2, 3
- Synergistic CNS depression beyond what either drug produces alone 4
- 3-4 times increased overdose risk compared to opioids alone 5
- Metabolic interactions that can lead to accumulation of toxic metabolites, particularly oxymorphone with chronic use 6
Both FDA drug labels carry boxed warnings specifically highlighting these dangers when these drug classes are combined 2, 3.
When Co-Prescription Cannot Be Avoided
If alternative treatment options are truly inadequate and you must prescribe both medications together, the CDC guidelines and FDA labels mandate specific risk mitigation strategies 1, 2, 3:
Prescribing Protocol
- Prescribe the lowest effective dosages of both medications
- Use minimum durations of concomitant therapy
- If starting diazepam in a patient on oxycodone: prescribe a lower initial benzodiazepine dose than usual and titrate slowly based on clinical response
- If starting oxycodone in a patient on diazepam: prescribe a lower initial opioid dose than usual and titrate slowly
Mandatory Monitoring
- Follow patients closely for signs of respiratory depression and sedation at frequent intervals
- Review prescription drug monitoring program (PDMP) data before prescribing and periodically during treatment (ideally before every prescription, at minimum every 3 months) 1
- Calculate total morphine milligram equivalents (MME) per day
Patient Safety Measures
- Prescribe naloxone for overdose reversal 1
- Counsel patients and caregivers about respiratory depression and sedation risks 2, 3
- Advise against driving or operating machinery until effects are known 3
- Screen for substance use disorders and warn about risks of adding alcohol or other CNS depressants 2
- Discuss that combining these medications increases mortality risk significantly 7
Recommended Alternatives
The evidence strongly supports seeking alternatives rather than combining these medications 1:
For Anxiety (Instead of Benzodiazepines)
- Serotonergic anxiolytics (SSRIs/SNRIs) - these are associated with lower co-prescription risk and better outcomes 8
- Non-pharmacologic interventions for anxiety management
- Coordinate with mental health specialists
For Pain (Instead of Opioids)
- Non-opioid analgesics
- Physical therapy and interventional pain management
- Consider that opioids have limited effectiveness for chronic non-cancer pain beyond 3 months 9
Critical Clinical Pitfalls
High-risk populations requiring extra caution 2:
- Elderly, cachectic, or debilitated patients (altered pharmacokinetics)
- Patients with chronic pulmonary disease, COPD, or compromised respiratory reserve
- Patients on high opioid doses (>150 mg MME/day have 1.7-2.7 times higher risk of co-prescription) 8
- Patients initiating buprenorphine for opioid use disorder (paradoxically at higher risk) 8
Avoid abrupt discontinuation - if you need to stop either medication after prolonged use, use gradual tapering to prevent potentially life-threatening withdrawal reactions 3. Short-term opioid dose reductions are associated with increased co-prescription risk, while longer-term reductions show protective effects 8.
Coordinate care - communicate with other prescribers managing the patient to discuss needs, prioritize goals, and weigh risks 1. Do not dismiss patients based on PDMP findings, as this creates missed opportunities for life-saving interventions 1.